Technology | EP Lab | October 13, 2016

Medtronic Cardiac Devices Gain FDA Approval for Full 3T MRI Scanning

Patients with SureScan pacemakers, ICDs and CRT-Ds now can receive 3 Tesla MRI scans

Medtronic, FDA approval, MRI, MR-conditional scanning, cardiac devices

October 13, 2016 — Medtronic plc is the first company to receive U.S. Food and Drug Administration (FDA) approval for its suite of cardiac rhythm and heart failure devices and leads to be scanned in both 3 and 1.5 Tesla (T) magnetic resonance imaging (MRI) machines. This advancement gives patients with Medtronic SureScan MR-conditional pacemakers, implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds) and leads access to MRI scans on any part of the body.

Each year, approximately 12-16 percent of patients with cardiac devices have a condition in which MRI would normally be prescribed, but less than 1 percent receive a scan because of device or lead restrictions. Before the availability of MR-conditional technology, patients with cardiac devices were contraindicated from undergoing MRI scans to avoid a potential interaction between the MRI and the device function.

"The potential interaction between cardiac devices and MRIs has been a long-running concern for patients and physicians," said Marc Silver, M.D., cardiologist at WakeMed Heart and Vascular Physicians in Raleigh, N.C. "Fortunately, advancements in MR-conditional cardiac device technology give patients more access to this important diagnostic tool."

MRI is an important imaging technology to diagnose conditions such as stroke, cancer, Alzheimer's disease, and muscle, bone and joint pain. 3T MRI offers better image quality, better diagnosis and reduced scan duration compared to 1.5T scans. In the next five years, the adoption of 3T MR systems is expected to reach approximately 30-40 percent of hospitals across the United States.

"While 1.5T scanners still comprise the majority of installations, 3T scanners are expected to comprise more than half of new units — with some centers having only 3T scanners — since they offer faster scans and higher resolution images," said Yair Safriel, M.D., neuroradiologist and chief medical officer at Pharmascan Clinical Trials and University of South Florida. "Approval for MRI-conditional scanning at both 1.5 and 3T allows patients to have improved access to MRI at a time and place most appropriate for their care. And with 3T scanning, physicians and radiologists gain a clearer look into soft tissues, particularly critical when diagnosing serious conditions, often involving the brain and spine."

Patients in the United States with the following devices are now eligible for 1.5 and 3T MRI scans:

  • Advisa MRI pacemakers and Micra transcatheter pacemaker
  • Amplia MRI and Compia MRI cardiac resynchronization therapy defibrillators
  • Evera MRI and Visia AF MRI DF-1 and DF4 implantable cardioverter defibrillators
  • Reveal LINQ insertable cardiac monitor
  • SureScan pacing, defibrillation and left-heart leads

Additionally, Medtronic now offers more options for ICD patients undergoing device replacement surgery, enabling MRI access to an even broader base of patients.

For more information: www.medtronic.com

Related Content

Philips, FDA, class I recall, HeartStart MRx Monitor/Defibrillator
News | Defibrillator Monitors| March 28, 2017
Philips and the U.S. Food and Drug Administration (FDA) announced the company has initiated a recall of its HeartStart...
Biotronik, Edora series, pacemakers, CRT-Ps
Technology | Cardiac Resynchronization Therapy Devices (CRT)| March 23, 2017
March 23, 2017 — Biotronik announced the European launch of the Edora series, its smallest series of...
closed loop stimulation, DDD-CLS, ACC17, SPAIN trial
Feature | Pacemakers| March 22, 2017
March 22, 2017 — Patients with recurrent fainting episodes (syncope) who received a pacemaker delivering a pacing pro
Aegis Medical Innovations, Sierra Ligation System, U.S. clinical trial, FDA approval, LAA occluder
Technology | Left Atrial Appendage (LAA) Occluders| March 22, 2017
Aegis Medical Innovations Inc. announced that it has received Investigational Device Exemption approval from the U.S....
Siemens Healthineers, ACC 2017, syngot CTO Guidance, Compressed Sensing Cardiac Cine
News | Cardiac Imaging| March 16, 2017
During the 66th Annual Scientific Session & Expo of the American College of Cardiology (ACC), March 17-19 in...
valve regurgitation, ASE, new guidelines, imaging, evaluation, SCMR, echocardiography, ultrasound, cardiac MRI
News | Cardiovascular Ultrasound| March 16, 2017
A new document from the American Society of Echocardiography (ASE) provides a comprehensive update to guide clinicians...
Medtronic, Reveal LINQ ICM, insertable cardiac monitor, FDA clearance, TruRhythm Detection
Technology | Implantable Cardiac Monitor (ICM)| March 15, 2017
Medtronic plc announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Reveal LINQ Insertable Cardiac...
heart monitoring technology, climbers, high altitudes, Circulation study, cardiac diagnostics, Medtronic, Reveal LINQ
News | Implantable Cardiac Monitor (ICM)| March 14, 2017
Climbing above 4,000 meters can provoke abnormal heart rhythms in otherwise healthy mountaineers, with the...
warfarin, anticoagulation therapy, atrial fibrillation patients, Duke Clinical Research Institute study, stroke
News | Antiplatelet and Anticoagulation Therapies| March 14, 2017
More than 80 percent of stroke patients with a history of atrial fibrillation either received not enough or no...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media| March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init